Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study
Yao Shuyang, Li Xiaoxue, Wang Chunxiu, Zhang Yi
Journal of Capital Medical University . 2022, (2): 289 -293 .  DOI: 10.3969/j.issn.1006-7795.2022.02.021